All In Biotech

Drug Trial Radar · NCT06935175

A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer

A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in Patients With Advanced Hepatocellular Cancer

Last checked: Nov 19, 2026Latest source record: Apr 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

53

Planned (sponsor's estimate)

Start

May 1, 2025

Primary completion

May 31, 2027

Study completion May 31, 2028

Sponsor

Lead sponsor
Shanghai Zhongshan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study was designed to evaluate the efficacy and safety of SHR-1826 monotherapy or in combination with immunotherapy in the treatment of advanced hepatocellular cancer patients.

Conditions

  • Hepatocellular Cancer

Interventions

  • SHR-1826Drug

    SHR-1826 will be administrated per dose level in which the patients are assigned.

  • SHR-1826 and immunotherapy combination therapyDrug

    SHR-1826 and immunotherapy will be administrated per dose level in which the patients are assigned.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) by RECIST V1.1Time frame: up 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Zhongshan Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.